Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy
about
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.Impact of urinary bladder cancer risk variants on prognosis and survival.Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin.Genetic Variants in the Insulin-like Growth Factor Pathway and Colorectal Cancer Risk in the Netherlands Cohort Study.The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer.Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment ResponseMicroRNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids.Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression.Association between polymorphisms in DNA repair gene XRCC1 and non-melanoma skin cancer risk: a meta-analysis.H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer.Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer.Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C.microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes.
P2860
Q35618177-11F7AD0B-BB09-4F4A-95E6-BF707B3B2355Q35717096-C0CBB5CB-2494-4122-898F-B19A6CE45472Q36046527-AAF9F4FE-D5AA-493D-91CC-FC7B233DCDBAQ36098447-DCDCD9CD-1BF7-47A9-A1B7-6ACFABB31164Q36328938-07D409F6-D865-4179-AD77-D06A89E41811Q37054113-0A5DF0D6-1146-490E-9292-7634A88F2CB5Q38613417-4C2D75D9-DD5C-4D35-AC7F-486D36E02A34Q38630652-CFFFFA98-8C73-477B-AEE1-72AFC08DE776Q38648987-48465C9B-65FA-4C4A-9B62-59CEDCF1F375Q39579247-FB9CDB79-B3C9-4A95-A567-0B49A3C296DDQ40427246-E6F120C2-9022-4B9B-870F-6E5DB714733CQ50567640-67A3B550-72C3-494A-BB00-33010620694DQ50780701-B3AD468D-F555-4F3A-9691-DD0235C796DCQ53636759-255C3062-799B-4294-862F-CD6E96772A7DQ55385354-D32A249F-9E56-4077-A75A-C658C90C8109
P2860
Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Polymorphisms in the XRCC1 gen ...... ents treated with chemotherapy
@en
Polymorphisms in the XRCC1 gen ...... nts treated with chemotherapy.
@nl
type
label
Polymorphisms in the XRCC1 gen ...... ents treated with chemotherapy
@en
Polymorphisms in the XRCC1 gen ...... nts treated with chemotherapy.
@nl
altLabel
Polymorphisms in theXRCC1gene ...... ents treated with chemotherapy
@en
prefLabel
Polymorphisms in the XRCC1 gen ...... ents treated with chemotherapy
@en
Polymorphisms in the XRCC1 gen ...... nts treated with chemotherapy.
@nl
P2093
P2860
P50
P356
P1476
Polymorphisms in the XRCC1 gen ...... ents treated with chemotherapy
@en
P2093
Andrea Bosio
Andrea Zitella
Angeline S Andrew
Barbara Pardini
Dario Fontana
Giovanni Casetta
Giuseppina Cucchiarale
Paolo Destefanis
Silvia Polidoro
Simonetta Guarrera
P2860
P304
P356
10.1002/IJC.28186
P407
P50
P577
2013-04-25T00:00:00Z